1993 Volume 42 Issue 3 Pages 151-156
To evaluate the usefulness for the detection of ischemic heart disease, ATP myocardial SPECT was perfomed in 35 patients (mean; 59±9.4 y.o.) with angina pectoris or old myocardial infarction. Coronary angiography (CAG) was performed in all patients.
The ultra-short half-life of ATP required a continuous infusion for its use. ATP was infused intravenously at a rate of 0.16 mg/kg/min for 5 min, with 201T1 injection taking place at 3 min. Myocardial SPECT imaging was begun 5 min and 4 h later after the end of ATP infusion.
ATP caused a significant decrease in arterial blood pressure (p<0.01) and reflex increase in heart rate (p<0.01) . Double product increased slightly (from 8394±2452 to 9581±1 856) .
The side effects were generally mild, transient, and no need for administration of aminophylline. The most frequent side effects include chest pain (26%), flushing, warmth (14%), headache (11%), palpitation (3%), dyspnea (3%), and arm discomfort (3%) . The second degree AV block was observed in 6% and ST depression was observed in 9% of patients.
Usefulness of ATP 201T1 myocardial SPECT for the detection of coronary artery disease (CAD) was evaluated using CAG as a golden standard. The sensitivity and specificiy for CAD detection were 82% and 90%, respectively. ATP myocardial SPECT is a promising new test for the detection of ischemic heart disease.
